UPLIZNA® (inebilizumab-cdon) is the first and only FDA-approved CD19+ B-cell-depleting monotherapy proven to reduce attacks in adult AQP4-IgG+ NMOSD patients. See safety info.| www.upliznahcp.com
Learn about UPLIZNA® (inebilizumab-cdon) treatment for your adult patients with immunoglobulin G4-related disease (IgG4-RD). See safety info.| www.upliznahcp.com